RxDoctor Payments Data

Elizabeth Abernathy

Hospitalist · Charlotte, NCNPI 1871518910

Payments from drug & device makers

$1,011in general payments, 2019–2025

Across 49 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$377
  • Novo Nordisk$109
  • Boston Scientific$72
  • Shockwave Medical, Inc$53
  • Insightec,inc$52
  • Abbott$50
  • plus $299 from 14 others

What the payments were for

  • Food & beverage$1,011100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,011 in reported general payments places this provider in the 80th percentile of 879 hospitalist providers in North Carolina.

See all hospitalist providers in North Carolina

Medicare billing

Part B allowed, 2024
$30,971
Medicare patients
63
Services billed
519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide22$22,868
EliquisApixaban16$13,566
XareltoRivaroxaban14$11,138
MyrbetriqMirabegron18$8,590
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,182
Rosuvastatin Calcium78$1,042
SynthroidLevothyroxine Sodium14$980
Ipratropium Bromide30$693
Amlodipine Besylate71$654
Trazodone Hcl34$621
Pravastatin Sodium24$556
Escitalopram Oxalate40$526
ValacyclovirValacyclovir Hcl18$494
Losartan Potassium19$473
Gabapentin40$417

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$33$22,86822 claims
PfizerEliquis, Paxlovid$14$13,56627 claims
AbbVieSynthroid$377$98014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 879 hospitalist providers in North Carolina.

Other hospitalist in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →